Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New developments in hormone replacement therapy].

R Winter1, U Haller, H Hepp

  • 1Universitätsklinik Graz. Geburtshilflich-gynäkologische Universitätsklinik, Auenbruggerplatz 14, AT-8036 Graz (Osterreich). @kfunigraz.ac.at

Gynakologisch-Geburtshilfliche Rundschau
|October 4, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Women "healthcare" and obstetrics - "thoughts of farewell"].

Zentralblatt fur Gynakologie·2006
Same author

[Contraception in young adolescents].

Gynakologisch-geburtshilfliche Rundschau·2005
Same author

Crash emergency cesarean section: decision-to-delivery interval under 30 min and its effect on Apgar and umbilical artery pH.

Archives of gynecology and obstetrics·2005
Same author

[Palliative medicine in gynecologic oncology].

Gynakologisch-geburtshilfliche Rundschau·2005
Same author

[Contraception and proception--competence of the gynaecologist in the planning of a woman's life].

Gynakologisch-geburtshilfliche Rundschau·2004
Same author

[Must the postgraduate medical training for specialists of gynecology and obstetrics be reconsidered?].

Gynakologisch-geburtshilfliche Rundschau·2004
Same journal

[Pelvic floor in pregnancy and after child birth: recommendations of the AUG Committee. Expert correspondence no. 29 of 31 July 2009].

Gynakologisch-geburtshilfliche Rundschau·2010
Same journal

[Water birth: control of infection and contraindications. Expert correspondence no. 27 of 26 May 2009].

Gynakologisch-geburtshilfliche Rundschau·2010
Same journal

[Current treatment options in postpartum hemorrhage. Expert correspondence no. 26 of 26 May 2009. ].

Gynakologisch-geburtshilfliche Rundschau·2010
Same journal

[Off label use of drugs in obstetric gynecology. 23rd consensus of of experts 19 October 2007].

Gynakologisch-geburtshilfliche Rundschau·2010
Same journal

[Hyperreactive luteomas during pregnancy--symptoms and complications: a case report].

Gynakologisch-geburtshilfliche Rundschau·2010
Same journal

[Paget disease of the vulva: resolution after local treatment with imiquimod--report of a case and review of the literature].

Gynakologisch-geburtshilfliche Rundschau·2010
See all related articles

Hormone replacement therapy does not protect against Alzheimer's disease or improve cognition. Long-term estrogen therapy may increase ovarian cancer risk.

Area of Science:

  • Neurology
  • Endocrinology
  • Oncology

Background:

  • Investigating the neuroprotective effects of hormone replacement therapy (HRT) in Alzheimer's disease (AD).
  • Evaluating the impact of combined estrogen and progesterone therapy on cognitive function.
  • Assessing the long-term risks associated with estrogen monotherapy.

Discussion:

  • Current evidence suggests HRT, including estrogen and progesterone, does not offer protection against AD.
  • Cognitive functioning remains unaffected by HRT in the studied populations.
  • Estrogen monotherapy, particularly with long-term use, is linked to a potential increase in ovarian cancer risk.

Key Insights:

  • Hormone replacement therapy is ineffective for Alzheimer's disease prevention.
  • No cognitive benefits were observed from HRT.

Related Experiment Videos

  • Estrogen monotherapy carries an elevated risk for ovarian cancer.

    • Outlook:

    • Further research is needed to explore alternative therapeutic strategies for AD.
    • Investigating the specific mechanisms underlying the lack of neuroprotection by HRT.
    • Continued surveillance for long-term adverse effects of hormone therapies.